Chronic thromboembolic pulmonary hypertension(CTEPH)is a chronic,progressive,debilitating,and life-threa-tening complication of pulmonary embolism(PE).Recent technological advances have permitted various treat-ment op...
Objective To compare the differences in pulmonary vascular morphological parameters between patients with chronic thromboembolic pulmonary disease(CTEPD)and chronic thromboembolic pulmonary hypertension(CTEPH),and to ...
Increasing evidence reports a greater incidence of stroke in patients with coronavirus disease 2019(COVID-19)than in the non-COVID-19 population and suggests that severe acute respiratory syndrome coronavirus 2(SARS-C...
Background and Aim: Mechanical prosthetic heart valves exert a lifelong thromboembolic complication requiring continuous antithrombotic therapy. Vitamin K antagonist is the recommended therapy of choice along with met...
BACKGROUND Several unique clinical features of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the cause of coronavirus disease 2019(COVID-19)infection,have been identified and characterized.One such featu...
Introduction: Venous thromboembolic disease (VTED), associating deep vein thrombosis and pulmonary embolism, represents a major public health issue. The objective of our work is to correlate confirmed...
Adult Nephrotic Syndrome (NS) is defined by proteinuria > 3 g/24h or 50 mg/kg/day, hypoprotidemia < 60 g/24h, hypoalbuminemia < 30 g/L. It is a disease with high thromboembolic risk. Peripheral vein thrombosis is comm...
BACKGROUND Little is unknown about the effect of chronic antithrombotic therapy(ATT)on bleeding complication during or after hepatectomy.In addition,the safety and effectiveness of chemical prevention for venous throm...
The use of dual antiplatelet therapy for the first three–six months after transcatheter aortic valve implantation (TAVI) has been suggested.~([1,2]) However, the additional benefit of anticoagulant therapy during the...
BACKGROUND Testicular germ cell tumor(TGCT)is the most curable solid tumor and most common cancer among men 18-39 years.While cisplatin-based chemotherapy has significantly lengthened the survival of patients with TGC...